RUNX2 and acute myeloid leukemia: To address the role of TP53INP2 in regulating the sensitivity of AML cells to TRAIL treatment, endogenous TP53INP2 was knocked down by a shTP53INP2 lentivirus in OCI-AML3 cells (Fig. 3a).